Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 45

1.

Association of Parkinson's disease-related pain with plasma interleukin-1, interleukin-6, interleukin-10, and tumour necrosis factor-α.

Li D, Song X, Huang H, Huang H, Ye Z.

Neurosci Lett. 2018 Jul 29;683:181-184. doi: 10.1016/j.neulet.2018.07.027. [Epub ahead of print]

PMID:
30063943
2.

Urate inhibits microglia activation to protect neurons in an LPS-induced model of Parkinson's disease.

Bao LH, Zhang YN, Zhang JN, Gu L, Yang HM, Huang YY, Xia N, Zhang H.

J Neuroinflammation. 2018 May 2;15(1):131. doi: 10.1186/s12974-018-1175-8.

3.

Interleukin-1β, interleukin-1 receptor antagonist, interleukin-6, interleukin-10, and tumor necrosis factor-α levels in CSF and serum in relation to the clinical diversity of Parkinson's disease.

Karpenko MN, Vasilishina AA, Gromova EA, Muruzheva ZM, Bernadotte A.

Cell Immunol. 2018 May;327:77-82. doi: 10.1016/j.cellimm.2018.02.011. Epub 2018 Feb 19.

PMID:
29478949
4.

TLR4 and TLR2 activation is differentially associated with age during Parkinson's disease.

Rocha Sobrinho HMD, Silva DJD, Gomides LF, Dorta ML, Oliveira MAP, Ribeiro-Dias F.

Immunol Invest. 2018 Jan;47(1):71-88. doi: 10.1080/08820139.2017.1379024. Epub 2017 Oct 27.

PMID:
29077524
5.

Protective role of chrysin on 6-hydroxydopamine-induced neurodegeneration a mouse model of Parkinson's disease: Involvement of neuroinflammation and neurotrophins.

Goes ATR, Jesse CR, Antunes MS, Lobo Ladd FV, Lobo Ladd AAB, Luchese C, Paroul N, Boeira SP.

Chem Biol Interact. 2018 Jan 5;279:111-120. doi: 10.1016/j.cbi.2017.10.019. Epub 2017 Oct 18.

PMID:
29054324
6.

Alternative microglial activation is associated with cessation of progressive dopamine neuron loss in mice systemically administered lipopolysaccharide.

Beier EE, Neal M, Alam G, Edler M, Wu LJ, Richardson JR.

Neurobiol Dis. 2017 Dec;108:115-127. doi: 10.1016/j.nbd.2017.08.009. Epub 2017 Aug 18.

PMID:
28823928
7.

Immune modulation by curcumin: The role of interleukin-10.

Mollazadeh H, Cicero AFG, Blesso CN, Pirro M, Majeed M, Sahebkar A.

Crit Rev Food Sci Nutr. 2017 Aug 11:1-13. doi: 10.1080/10408398.2017.1358139. [Epub ahead of print]

PMID:
28799796
8.

Interleukin-10 inhibits neuroinflammation-mediated apoptosis of ventral mesencephalic neurons via JAK-STAT3 pathway.

Zhu Y, Liu Z, Peng YP, Qiu YH.

Int Immunopharmacol. 2017 Sep;50:353-360. doi: 10.1016/j.intimp.2017.07.017. Epub 2017 Jul 25.

PMID:
28753520
9.

Multiple lipopolysaccharide (LPS) injections alter interleukin 6 (IL-6), IL-7, IL-10 and IL-6 and IL-7 receptor mRNA in CNS and spleen.

Szot P, Franklin A, Figlewicz DP, Beuca TP, Bullock K, Hansen K, Banks WA, Raskind MA, Peskind ER.

Neuroscience. 2017 Jul 4;355:9-21. doi: 10.1016/j.neuroscience.2017.04.028. Epub 2017 Apr 27.

PMID:
28456715
10.

Treg Cells Protect Dopaminergic Neurons against MPP+ Neurotoxicity via CD47-SIRPA Interaction.

Huang Y, Liu Z, Cao BB, Qiu YH, Peng YP.

Cell Physiol Biochem. 2017;41(3):1240-1254. doi: 10.1159/000464388. Epub 2017 Mar 7.

11.

Aberrations in Peripheral Inflammatory Cytokine Levels in Parkinson Disease: A Systematic Review and Meta-analysis.

Qin XY, Zhang SP, Cao C, Loh YP, Cheng Y.

JAMA Neurol. 2016 Nov 1;73(11):1316-1324. doi: 10.1001/jamaneurol.2016.2742. Review.

PMID:
27668667
12.

Cerebrospinal Fluid Biomarkers in Highly Exposed PM2.5 Urbanites: The Risk of Alzheimer's and Parkinson's Diseases in Young Mexico City Residents.

Calderón-Garcidueñas L, Avila-Ramírez J, Calderón-Garcidueñas A, González-Heredia T, Acuña-Ayala H, Chao CK, Thompson C, Ruiz-Ramos R, Cortés-González V, Martínez-Martínez L, García-Pérez MA, Reis J, Mukherjee PS, Torres-Jardón R, Lachmann I.

J Alzheimers Dis. 2016 Sep 6;54(2):597-613. doi: 10.3233/JAD-160472.

PMID:
27567860
13.

Inflammatory profile in LRRK2-associated prodromal and clinical PD.

Brockmann K, Apel A, Schulte C, Schneiderhan-Marra N, Pont-Sunyer C, Vilas D, Ruiz-Martinez J, Langkamp M, Corvol JC, Cormier F, Knorpp T, Joos TO, Gasser T, Schüle B, Aasly JO, Foroud T, Marti-Masso JF, Brice A, Tolosa E, Marras C, Berg D, Maetzler W.

J Neuroinflammation. 2016 May 24;13(1):122. doi: 10.1186/s12974-016-0588-5.

14.

Lack of association between IL-10 and IL-18 gene promoter polymorphisms and Parkinson's disease with cognitive impairment in a Chinese population.

Liu Z, Guo J, Wang Y, Li K, Kang J, Wei Y, Sun Q, Xu Q, Xu C, Yan X, Tang B.

Sci Rep. 2016 Feb 2;6:19021. doi: 10.1038/srep19021.

15.

Interleukin-10 Protection against Lipopolysaccharide-Induced Neuro-Inflammation and Neurotoxicity in Ventral Mesencephalic Cultures.

Zhu Y, Chen X, Liu Z, Peng YP, Qiu YH.

Int J Mol Sci. 2015 Dec 28;17(1). pii: E25. doi: 10.3390/ijms17010025.

16.

A dysfunction of CD4+ T lymphocytes in peripheral immune system of Parkinson's disease model mice.

Huang Y, Liu Z, Wang XQ, Qiu YH, Peng YP.

Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2014 Nov;30(6):567-76.

PMID:
26016368
17.

The interleukin 1 alpha, interleukin 1 beta, interleukin 6 and alpha-2-macroglobulin serum levels in patients with early or late onset Alzheimer's disease, mild cognitive impairment or Parkinson's disease.

Dursun E, Gezen-Ak D, Hanağası H, Bilgiç B, Lohmann E, Ertan S, Atasoy İL, Alaylıoğlu M, Araz ÖS, Önal B, Gündüz A, Apaydın H, Kızıltan G, Ulutin T, Gürvit H, Yılmazer S.

J Neuroimmunol. 2015 Jun 15;283:50-7. doi: 10.1016/j.jneuroim.2015.04.014. Epub 2015 Apr 25.

PMID:
26004156
18.

Transcription factor myocyte enhancer factor 2D regulates interleukin-10 production in microglia to protect neuronal cells from inflammation-induced death.

Yang S, Gao L, Lu F, Wang B, Gao F, Zhu G, Cai Z, Lai J, Yang Q.

J Neuroinflammation. 2015 Feb 20;12:33. doi: 10.1186/s12974-015-0258-z.

19.

The therapeutic potential of interleukin-10 in neuroimmune diseases.

Kwilasz AJ, Grace PM, Serbedzija P, Maier SF, Watkins LR.

Neuropharmacology. 2015 Sep;96(Pt A):55-69. doi: 10.1016/j.neuropharm.2014.10.020. Epub 2014 Nov 4. Review.

20.

The influence of AAV2-mediated gene transfer of human IL-10 on neurodegeneration and immune response in a murine model of Parkinson's disease.

Joniec-Maciejak I, Ciesielska A, Wawer A, Sznejder-Pachołek A, Schwenkgrub J, Cudna A, Hadaczek P, Bankiewicz KS, Członkowska A, Członkowski A.

Pharmacol Rep. 2014 Aug;66(4):660-9. doi: 10.1016/j.pharep.2014.03.008. Epub 2014 Apr 8.

PMID:
24948069

Supplemental Content

Loading ...
Support Center